RET and non-small cell lung carcinoma: As we anticipate an increase in the importance of screening for RET fusion-positive non-squamous NSCLC with the regulatory approval of highly specific RET inhibitors, either using single gene or multigene tests, we have reviewed the practices that ensure optimal access to the entire spectrum of relevant biomarkers in NSCLC clinical samples.